Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

Summary: This is a randomized, double-blinded, controlled Phase I study of CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of CMAB015 versus Cosentyx（Secukinumab ） in healthy male subjects after a single dose.
clinicaltrials.gov

Short title: Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
clinicaltrials.gov

Official title: Phase I Comparison of Pharmacokinetics, Safety, and Immunogenicity of CMAB015 Injection and Cosentyx in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male Subjects
clinicaltrials.gov

Control arm: Active comparator
clinicaltrials.gov

Registry reports results: No
clinicaltrials.gov

Listing at source: Listed
clinicaltrials.gov

Recruitment status: Completed
clinicaltrials.gov

Phase: Phase 1
clinicaltrials.gov

Study type: Interventional
clinicaltrials.gov

Completion date: 2023-07-03
clinicaltrials.gov

First posted: 2023-02-21
clinicaltrials.gov

Registry last updated: 2024-04-10
clinicaltrials.gov

Primary completion date: 2023-07-03
clinicaltrials.gov

Start date: 2023-02-15
clinicaltrials.gov

Actual participants: 130
clinicaltrials.gov

Participants: 130
clinicaltrials.gov

Participant count basis: Actual
clinicaltrials.gov

Protocol amendments: 1
clinicaltrials.gov

Randomisation ratio: 1:1
clinicaltrials.gov

Number of sites: 1
clinicaltrials.gov

Data monitoring committee: No
clinicaltrials.gov

Registry sponsor category: Industry
clinicaltrials.gov

Lead sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
clinicaltrials.gov

Source registry: ClinicalTrials.gov
clinicaltrials.gov

Registry ID: NCT05734482
clinicaltrials.gov

ClinicalTrials.gov ID: NCT05734482
clinicaltrials.gov

Registry record: Open registry record
clinicaltrials.gov

Allocation: Randomised
Model: Parallel groups
Purpose: Treatment
Masking: Triple masking
Masked roles: Participants, Care providers, Investigators

Sources for study design

clinicaltrials.gov

Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time
Timeframe: up to 2688 hours
Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single injection of CMAB015/Cosentyx
Maximum Concentration of Secukinumab
Timeframe: up to 2688 hours
Maximum Concentration of Secukinumab After the Single Injection of CMAB015/Cosentyx

Time to Maximum Concentration of Secukinumab
Timeframe: up to 2688 hours
Time to Maximum Concentration of Secukinumab after the Single Injection of CMAB015/Cosentyx
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2688 Hours
Timeframe: up to 2688 hours
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2688 Hours After the Single Injection of CMAB015/Cosentyx
Half time
Timeframe: up to 2688 hours
Half-time after the Single Injection of CMAB015/Cosentyx
Clearance Rate
Timeframe: up to 2688 hours
Clearance Rate after the Single Injection of CMAB015/Cosentyx
Apparent Volume of Distribution
Timeframe: up to 2688 hours
Apparent Volume of Distribution after the Single Injection of CMAB015/Cosentyx
Terminal phase elimination rate constant
Timeframe: up to 2688 hours
Terminal phase elimination rate constant after the Single Injection of CMAB015/Cosentyx
anti-drug antibodies(ADA)
Timeframe: up to 2688 hours
ADA Positive Rate after the Single Injection of CMAB015/Cosentyx
Neutralization antibodies(Nab)
Timeframe: up to 2688 hours
Neutralizing Antibody Positive Rate after the Single Injection of CMAB015/Cosentyx
Percentage of participants with Adverse Events
Timeframe: up to 2688 hours
Total Frequency of Adverse Events/Serious Adverse Events Within the Whole Time of the Study

Sources for outcomes

clinicaltrials.gov

Sex: Male
Age groups: Adults
Minimum age: 18 Years
Maximum age: 45 Years
Healthy volunteers: Yes

Healthy male volunteers, age ranged 18 to 45 years (both inclusive)；
Subjects with body weight of ≥50 kg and ≤ 75 kg and BMI ≥18 and <28 kg/m2 ;
Subjects and their partners were willing to use medically approved contraceptive methods within 6 months of study administration, partners did not plan to become pregnant, subjects did not plan to donate sperm；
The subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; Moreover, the subjects can communicate well with researchers and complete the research according to the regulations；
Subjects voluntarily sign ICF prior to the study.

After comprehensive examination (vital signs, physical examination, electrocardiogram, chest radiography, abdominal B-ultrasound, blood routine, urine routine, blood biochemistry, etc.), any examination item was judged abnormal by the investigator and had clinical significance;
Patients with serious diseases such as cardiovascular system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematopoietic system, immune system, or any of the above diseases；
Patients with currently active infected diseases；
Subjects with past or current inflammatory bowel disease;
History of malignant neoplasms within the last 5 years (other than completely resected basal cell or squamous cell carcinoma of the skin in situ)；
Any one of HBV surface antigen, HCV antibody, HIV antibody, treponema pallidum antibody positive；
Subjects with T-SPOT test positive；
Those who smoked more than 5 cigarettes per day in the 6 months before screening and did not cooperate with smoking bans during the study period；
Alcoholics，or participants who consumed more than 14 units of alcohol per week (1 unit = 17.7mL ethanol, i.e., 1 unit = 357mL 5% beer or 43mL 40% liquor or 147mL 12% wine) during the preceding 3 months were screened，or who have positive result in blood-test of alcohol or not willing to ban alcohol；
Drug abusers, or drug users in the 3 months prior to screening, or excessive daily consumption of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250mL) in the 3 months prior to screening, or positive urine drug screening；
Surgery within 4 weeks prior to screening; Or plan to have surgery during the study period；
Use of any prescription drug, over-the-counter drug or health product within 4 weeks prior to screening, or prior use of such drug or health product within 5 half-lives, whichever is longer；
Those who have used any biological agent, including live vaccine, in the 3 months prior to screening, or who plan to receive live vaccine during the study period；
Anti-il-17 antibody active ingredient, excipients or latex allergy；
Those with anti-IL-17 antibody and anti-drug antibody positive；
Those who have been enrolled in other clinical studies or less than 3 months since the end of the most recent clinical study；
Those who had lost blood or donated at least 400 mL in the 3 months prior to the trial, or had lost blood or donated at least 200 mL in the 1 month prior to screening, or planned to donate blood during the trial；
Those who Can not tolerate venipunction, has a history of dizziness of needle and blood；
Those who have special dietary requirements, or can not accept uniform diet；
Other conditions considered inappropriate to be included in this study.